A look at the headlines right now:
- India is not only meeting Paris Agreement target, but also exceeding them, says PM Modi: He also spoke about India’s effort to eliminate single-use plastics and pointed out that forests were expanding in the country, where the population of lions and tigers was also increasing.
- Kerala governor signs ordinance to allow five-year jail term for offensive social media posts: A person found creating or sending content that is offensive or intended to offend or threaten another person may face five years in prison, a fine of Rs 10,000, or both.
- Covaxin will be at least 60% effective, says Bharat Biotech: The company said that while it aimed to achieve at least 60% efficacy, it could actually be more.
- Are inter-faith marriages in families of BJP leaders also ‘love jihad’, asks Bhupesh Baghel: Five BJP-ruled states – Uttar Pradesh, Haryana, Madhya Pradesh, Karnataka and Assam – have promised to introduced strict legal provisions to prevent “love jihad”.
- Congress should hold polls if it wants to become a national alternative, says Ghulam Nabi Azad: Kapil Sibal, meanwhile, said the party was no longer an effective opposition.
- At 6.9 degrees Celsius, Delhi experiences coldest November in 17 years: The last time it was this cold in November was in 2003, when the city recorded a minimum of 6.1 degrees Celsius.
- Patricia Mukhim’s case a reflection of larger threats to freedom of speech in India, says Editors Guild: The statement came days after the journalist resigned from the guild protesting against ‘selective discrimination’.
- Tejashwi Yadav faces corruption charges, should not become leader of opposition, says JD(U): Party leaders criticised Yadav for targeting Chief Minister Nitish Kumar over appointing Mewa Lal Chaudhary the education minister.
- IMA condemns Centre’s move to allow Ayurveda doctors to perform surgeries: The doctors’ association also urged the Centre to refrain from posting doctors of modern medicine at Indian medicine colleges.
- Moderna to charge $25-$37 for its coronavirus vaccine, says CEO: The vaccine candidate was found to be 94.5% effective against the virus during its phase three trials.
Buy an annual Scroll Membership to support independent journalism and get special benefits.
Our journalism is for everyone. But you can get special privileges by buying an annual Scroll Membership. Sign up today!